Patents by Inventor Jeffrey A. Hubbell

Jeffrey A. Hubbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10471155
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: November 12, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10392437
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: August 27, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10335499
    Abstract: Block copolymers containing charged blocks or chemical moieties sensitive to oxidation or hydrolysis have been developed. We describe the use of such block copolymers in supramolecular structures, e.g., micelles or vesicles, and pharmaceutical compositions and in methods of preparing the supramolecular structures and pharmaceutical compositions. The invention is particularly useful for the delivery of pharmaceutical agents, e.g., nucleic acids, to cells.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: July 2, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: James Brandon Dixon, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
  • Publication number: 20190117838
    Abstract: The invention relates to methods for producing a polymeric scaffold for use in tissue engineering applications or soft tissue surgery, as wellto the produced scaffolds and an associated kit. The method features a first fast drying step of applying a as mechanical compression on a polymeric gel layer and a second slow drying step of the gel up to reach a polymer mass fraction of at least 60% w/w in the final scaffold. The method allows the production of scaffolds with high regeneration and healing properties of a grafted tissue via host cell invasion and colonization, and a good suturability. These goals are achieved through the formation within the scaffold of a non-uniform architecture creating softer and stiffer areas, which is maintained even upon re-swelling of the scaffold upon hydration of the final dried product.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 25, 2019
    Inventors: Peter FREY, Jeffrey A. HUBBELL, Hans M. LARSSON, Elif VARDAR, Eva-Maria BALET, Ganesh VYTHILINGHAM, Kalitha PINNAGODA
  • Patent number: 10265415
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 23, 2019
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 10265416
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 23, 2019
    Assignee: École Polytechnique Fédérale de Lausanna (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Publication number: 20190099485
    Abstract: The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.
    Type: Application
    Filed: April 28, 2017
    Publication date: April 4, 2019
    Inventors: Melody A. Swartz, Jeffrey A. Hubbell, Shann Yu, Efthymia Vokali, Manuel Fankhauser, Sachiko Hirosue, Priscilla S. Briquez, Maria Broggi, Lambert Potin, Maria Stella Sasso
  • Publication number: 20180303951
    Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Application
    Filed: July 5, 2018
    Publication date: October 25, 2018
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Publication number: 20180280524
    Abstract: Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 4, 2018
    Inventors: Jeffrey A. Hubbell, David Scott Wilson, Sachiko Hirosue
  • Publication number: 20180271986
    Abstract: Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Application
    Filed: March 19, 2018
    Publication date: September 27, 2018
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Patent number: 10046056
    Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: August 14, 2018
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Publication number: 20180185507
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 5, 2018
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Publication number: 20180185505
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 5, 2018
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Publication number: 20180185508
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 5, 2018
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Publication number: 20180100011
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Application
    Filed: November 21, 2017
    Publication date: April 12, 2018
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 9901646
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: February 27, 2018
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 9901645
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: February 27, 2018
    Assignee: Ecole Polytechnique Fedrale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 9879062
    Abstract: Embodiments of the invention are described, including materials and methods for making molecules and materials that have a specific binding domain of a PlGF2. Embodiments include, for instance, medicaments, biomaterials, biomolecules, molecular fusions, and vaccines.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 30, 2018
    Assignee: Ecole Polytechnique Federale De Lausanne
    Inventors: Jeffrey A. Hubbell, Mikael Martino, Priscilla S. Maithili Briquez
  • Patent number: 9878048
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: January 30, 2018
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 9850296
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: December 26, 2017
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane